PepsiCo investors are zeroing in on the company’s upcoming earnings release, hungry for two things above all: dependable demand signals from consumers and evidence that management is keeping a tight grip on costs. The stock edged up 0.5% in European trading to EUR 115.16, a modest move that masks a far more complicated story underneath.
That story increasingly revolves around a force no consumer staples giant can control — the rapid adoption of GLP-1 weight-loss medications and what it means for the snack aisle.
A $73 Billion Question Mark
Fresh research puts the value at risk across the global food sector from GLP-1 weight-loss drugs at roughly USD 73 billion. The figure has injected a new layer of caution into how the market views legacy snack brands, PepsiCo’s among them. Households in the United States that began such treatments cut their snack spending by an average of 10%, according to findings published in the Journal of Marketing Research. For a company that leans heavily on its North American home market, that is a meaningful drag on near-term volume growth expectations.
The broader backdrop is no easier. Consumers are watching their wallets more carefully, and affordability pressure continues to weigh on sentiment. Against that, Morningstar analyst Kristoffer Inton argued in a note published yesterday that short-term hurdles are currently overshadowing the genuine opportunities PepsiCo holds in innovation and international markets.
Morningstar Keeps Its Top Marks
Even with those headwinds, Morningstar maintains its highest rating for competitive advantages on the company. The foundation rests on well-known beverage and snack brands, extensive scale in procurement and distribution, and deeply entrenched relationships with retailers. Inton singled out the snack portfolio as particularly well positioned to capture additional market share, citing strong brand recognition and operational muscle.
Carbonated soft drinks remain the tougher battleground. PepsiCo has yet to close the gap with rival Coca-Cola in that core category. To spark growth beyond fizzy drinks, management is weighing new in-house product lines alongside licensing deals with third parties for non-carbonated offerings — moves aimed at broadening its reach and squeezing more out of its distribution network.
Should investors sell immediately? Or is it worth buying PepsiCo?
Valuation Tells Its Own Story
The stock’s recent stabilization at EUR 115.18 leaves it just 3.3% above its 52-week low of EUR 111.52, a proximity that speaks to how much investor anxiety has built up. Set against its 52-week high, the shares sit 21% lower — a discount that already prices in a good deal of the worry.
Several factors have weighed on the stock of late. Roughly three weeks ago, the company reassigned its global media account. On the financial side, PepsiCo leans on a solid liquidity base, and with a price-to-earnings ratio of 17.1, market watchers point to potential efficiency gains from global service centers and streamlined supply chains in an optimistic scenario.
Offsetting that, declining legacy core brands and shifting dietary habits remain significant valuation factors. Whether the expansion of higher-margin categories can offset the structural shift in consumer goods depends on how quickly the new product strategy gets executed.
A Dividend Track Record That Keeps Giving
For income-focused investors, the stock still carries defensive appeal. PepsiCo has now raised its dividend for 54 consecutive years, a streak that provides a measure of comfort while the demand picture sorts itself out. Whether sentiment brightens on a lasting basis will hinge largely on how demand and margin stability evolve from here.
Ad
PepsiCo Stock: Buy or Sell?! New PepsiCo Analysis from September 23 delivers the answer:
The latest PepsiCo figures speak for themselves: Urgent action needed for PepsiCo investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 23.
PepsiCo: Buy or sell? Read more here...
